MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:04Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 15:		Line 15:
	\| legal = Rx-only in US		\| legal = Rx-only in US
	\| mechanism = Selective inhibitor of phosphodiesterase type 5 (PDE5); increases cGMP in cavernous smooth muscle, producing erection in response to sexual stimulation.		\| mechanism = Selective inhibitor of phosphodiesterase type 5 (PDE5); increases cGMP in cavernous smooth muscle, producing erection in response to sexual stimulation.
	\| intro = Avanafil is the newest of the four FDA-approved PDE5 inhibitors (2012). Compared to [[Sildenafil]] and [[Vardenafil]], it has a faster onset (~15 min) and is more selective for PDE5 over PDE6 (fewer visual side effects). Compared to [[Tadalafil]], it has a shorter duration — better suited to as-needed use than continuous coverage.		\| intro = Avanafil is the newest of the four FDA-approved PDE5 inhibitors (2012). Compared to [[Sildenafil]] and [[Vardenafil]], it has a faster onset (~15 min) and is more selective for PDE5 over PDE6 (fewer visual side effects). Compared to [[Tadalafil]], it has a shorter duration, better suited to as-needed use than continuous coverage.
	\| indications =		\| indications =
	\| dosing =		\| dosing =

MDElliottMD: Create Avanafil scaffold

2026-05-15T15:30:21Z

Create Avanafil scaffold

New page

{{MedTemplate
| generic = Avanafil
| brand = Stendra
| classes = PDE5 Inhibitor
| uses = <vote slug="erectile-dysfunction-use">Erectile dysfunction</vote>
| starting_dose = 100 mg ~15 min before sexual activity
| preparations = 50, 100, 200 mg tabs
| fda_max = 200 mg/d (100 mg/d if on CYP3A4 inhibitors)
| routes = Oral
| onset = ~15 min (fastest of the PDE5 inhibitors)
| duration = 4–6 h
| halflife = ~5 h
| bioavailability = Rapid absorption; absolute bioavailability not formally established
| pregnancy = Category C (not relevant; not used in women)
| legal = Rx-only in US
| mechanism = Selective inhibitor of phosphodiesterase type 5 (PDE5); increases cGMP in cavernous smooth muscle, producing erection in response to sexual stimulation.
| intro = Avanafil is the newest of the four FDA-approved PDE5 inhibitors (2012). Compared to [[Sildenafil]] and [[Vardenafil]], it has a faster onset (~15 min) and is more selective for PDE5 over PDE6 (fewer visual side effects). Compared to [[Tadalafil]], it has a shorter duration — better suited to as-needed use than continuous coverage.
| indications =
| dosing =
| effects =
| pk_absorption = Rapid; peak ~30–45 min.
| pk_distribution = Plasma protein binding ~99%.
| pk_metabolism = Hepatic via CYP3A4 (primary), CYP2C9 (minor).
| pk_elimination = Mainly fecal as inactive metabolites.
| pharmacodynamics =
| interactions = <pharmaInteractions/>
| pregnancy_details =
| monitoring = Blood pressure with concurrent antihypertensives or alpha-blockers.
| counseling = Contraindicated with any nitrate (life-threatening hypotension). Caution with alpha-blockers.
| anecdotes =
| seealso = [[Sildenafil]], [[Tadalafil]], [[Vardenafil]]
| references = <references/>
}}

[[Category:PDE5 Inhibitors]]
[[Category:Medicines]]

Avanafil - Revision history

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

MDElliottMD: Create Avanafil scaffold